Lady  	Lady  	 NNP	B-NP
Prelox®  	Prelox®  	 NNP	I-NP
improves  	improves  	 VBZ	O
sexual  	sexual  	 JJ	B-NP
function  	function  	 NN	I-NP
in  	in  	 IN	O
post-menopausal  	post-menopausal  	 JJ	B-NP
women  	women  	 NNS	I-NP
The  	The  	 DT	O
aim  	aim  	 NN	O
of  	of  	 IN	O
this  	this  	 DT	O
pilot 	pilot 	 NN	O
,  	,  	 ,	O
single-blinded  	single-blinded  	 JJ	O
study  	study  	 NN	O
was  	was  	 VBD	O
to  	to  	 TO	O
evaluate  	evaluate  	 VB	O
the  	the  	 DT	O
efficacy  	efficacy  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
proprietary 	proprietary 	 NN	O
,  	,  	 ,	O
dietary  	dietary  	 JJ	B-NP
supplement  	supplement  	 NN	I-NP
Lady  	Lady  	 NNP	I-NP
Prelox®  	Prelox®  	 NNP	I-NP
for  	for  	 IN	O
supporting  	supporting  	 VBG	O
and  	and  	 CC	O
improving  	improving  	 VBG	O
sexual  	sexual  	 JJ	B-NP
function  	function  	 NN	I-NP
in  	in  	 IN	O
generally  	generally  	 RB	O
healthy 	healthy 	 JJ	O
,  	,  	 ,	O
post-menopausal  	post-menopausal  	 JJ	B-NP
women 	women 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
Lady  	Lady  	 NNP	B-NP
Prelox®  	Prelox®  	 NNP	I-NP
and  	and  	 CC	O
placebo  	placebo  	 JJ	O
control  	control  	 NN	O
groups  	groups  	 NNS	O
were  	were  	 VBD	O
comparable  	comparable  	 JJ	O
at  	at  	 IN	O
inclusion  	inclusion  	 NN	O
with  	with  	 IN	O
regard  	regard  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
total  	total  	 JJ	B-NP
Female  	Female  	 NNP	I-NP
Sexual  	Sexual  	 NNP	I-NP
Function  	Function  	 NNP	I-NP
Index  	Index  	 NNP	I-NP
( 	( 	 -LRB-	O
FSFI 	FSFI 	 NNP	B-NP
)  	)  	 -RRB-	O
score 	score 	 NN	O
,  	,  	 ,	O
as  	as  	 RB	O
well  	well  	 RB	O
as  	as  	 RB	O
for  	for  	 IN	O
the  	the  	 DT	O
six  	six  	 CD	O
individual  	individual  	 JJ	B-NP
FSFI  	FSFI  	 NNP	I-NP
domains 	domains 	 NN	I-NP
,  	,  	 ,	O
with  	with  	 IN	O
40  	40  	 CD	O
women  	women  	 NNS	O
( 	( 	 -LRB-	O
50.1  	50.1  	 CD	O
±  	±  	 CD	O
3.1  	3.1  	 CD	O
years 	years 	 NNS	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
43  	43  	 CD	O
women  	women  	 NNS	O
( 	( 	 -LRB-	O
51.2  	51.2  	 CD	O
±  	±  	 CD	O
2.3  	2.3  	 CD	O
years 	years 	 NNS	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
At  	At  	 IN	O
baseline  	baseline  	 VBG	O
the  	the  	 DT	O
women  	women  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
verum  	verum  	 JJ	B-NP
group  	group  	 NN	I-NP
presented  	presented  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
mean  	mean  	 JJ	O
total  	total  	 JJ	B-NP
FSFI  	FSFI  	 NNP	I-NP
score  	score  	 NN	I-NP
of  	of  	 IN	O
44.6  	44.6  	 CD	O
±  	±  	 CD	O
24.1  	24.1  	 CD	O
which  	which  	 WDT	O
increased  	increased  	 VBD	O
significantly  	significantly  	 RB	O
already  	already  	 RB	O
after  	after  	 IN	O
four  	four  	 CD	O
weeks  	weeks  	 NNS	B-NP
treatment  	treatment  	 NN	I-NP
with  	with  	 IN	O
Lady  	Lady  	 NNP	B-NP
Prelox®  	Prelox®  	 NNP	I-NP
to  	to  	 TO	O
70.9  	70.9  	 CD	O
±  	±  	 CD	O
18.5  	18.5  	 CD	O
and  	and  	 CC	O
further  	further  	 RB	O
increased  	increased  	 VBN	O
to  	to  	 TO	O
71.7  	71.7  	 CD	O
±  	±  	 CD	O
23.9  	23.9  	 CD	O
after  	after  	 IN	O
completion  	completion  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
eight-week  	eight-week  	 JJ	B-NP
trial  	trial  	 NN	I-NP
period 	period 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
control  	control  	 NN	B-NP
group  	group  	 NN	I-NP
the  	the  	 DT	O
mean  	mean  	 JJ	O
total  	total  	 JJ	B-NP
FSFI  	FSFI  	 NNP	I-NP
was  	was  	 VBD	O
44.1  	44.1  	 CD	O
±  	±  	 CD	O
22.8  	22.8  	 CD	O
at  	at  	 IN	O
inclusion  	inclusion  	 NN	O
and  	and  	 CC	O
non-significantly  	non-significantly  	 NNP	B-NP
increased  	increased  	 VBD	O
to  	to  	 TO	O
45  	45  	 CD	O
±  	±  	 CD	O
21.4  	21.4  	 CD	O
after  	after  	 IN	O
four  	four  	 CD	O
weeks  	weeks  	 NNS	O
and  	and  	 CC	O
47.4  	47.4  	 CD	O
±  	±  	 CD	O
21.8  	21.8  	 CD	O
after  	after  	 IN	O
eight  	eight  	 CD	O
weeks 	weeks 	 NNS	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
The  	The  	 DT	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
Lady  	Lady  	 NNP	B-NP
Prelox®  	Prelox®  	 NNP	I-NP
was  	was  	 VBD	O
comparatively  	comparatively  	 RB	O
significantly  	significantly  	 RB	O
more  	more  	 RBR	O
effective  	effective  	 JJ	O
than  	than  	 IN	O
placebo  	placebo  	 NN	O
after  	after  	 IN	O
both  	both  	 DT	O
four  	four  	 CD	O
and  	and  	 CC	O
eight  	eight  	 CD	O
weeks  	weeks  	 NNS	O
of  	of  	 IN	O
treatment  	treatment  	 NN	O
( 	( 	 -LRB-	O
P  	P  	 NNP	O
< 	< 	 SYM	O
0.05 	0.05 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
individual  	individual  	 JJ	O
six  	six  	 CD	O
FSFI  	FSFI  	 NNS	B-NP
domains  	domains  	 VBP	I-NP
related  	related  	 VBN	O
to  	to  	 TO	O
desire 	desire 	 NN	O
,  	,  	 ,	O
arousal 	arousal 	 NN	B-NP
,  	,  	 ,	O
lubrication 	lubrication 	 NN	O
,  	,  	 ,	O
orgasm 	orgasm 	 NN	O
,  	,  	 ,	O
satisfaction  	satisfaction  	 NN	B-NP
and  	and  	 CC	O
pain  	pain  	 NN	O
did  	did  	 VBD	O
all  	all  	 RB	O
respond  	respond  	 VB	O
favourably  	favourably  	 VBN	O
to  	to  	 TO	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
Lady  	Lady  	 NNP	B-NP
Prelox® 	Prelox® 	 NNP	I-NP
;  	;  	 :	O
however 	however 	 RB	O
,  	,  	 ,	O
with  	with  	 IN	O
only  	only  	 RB	O
marginable  	marginable  	 VB	O
higher  	higher  	 JJR	O
scores  	scores  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
placebo  	placebo  	 JJ	O
group 	group 	 NN	O
.  	.  	 .	O
Four  	Four  	 CD	O
women  	women  	 NNS	O
in  	in  	 IN	O
each  	each  	 DT	O
group  	group  	 NN	O
dropped  	dropped  	 VBD	O
out  	out  	 RP	O
because  	because  	 IN	O
of  	of  	 IN	O
inabilities  	inabilities  	 VBG	O
to  	to  	 TO	O
attend  	attend  	 VB	O
scheduled  	scheduled  	 VBN	O
check-ups 	check-ups 	 JJ	O
.  	.  	 .	O
No  	No  	 DT	O
adverse  	adverse  	 JJ	O
effects  	effects  	 NNS	O
were  	were  	 VBD	O
reported 	reported 	 VBN	O
.  	.  	 .	O
This  	This  	 DT	O
study  	study  	 NN	O
opens  	opens  	 VBZ	O
an  	an  	 DT	O
interesting  	interesting  	 JJ	O
perspective  	perspective  	 NN	O
for  	for  	 IN	O
women  	women  	 NNS	O
experiencing  	experiencing  	 VBG	O
moderate  	moderate  	 JJ	O
sexual  	sexual  	 JJ	B-NP
function  	function  	 NN	I-NP
impairment  	impairment  	 NN	I-NP
and  	and  	 CC	O
suggests  	suggests  	 VBZ	O
a  	a  	 DT	O
promising  	promising  	 JJ	O
new  	new  	 JJ	O
treatment  	treatment  	 NN	B-NP
option 	option 	 NN	I-NP
.  	.  	 .	O
Further  	Further  	 JJ	B-NP
studies  	studies  	 NNS	I-NP
with  	with  	 IN	O
larger  	larger  	 JJR	O
numbers  	numbers  	 NNS	O
of  	of  	 IN	O
women 	women 	 NNS	O
,  	,  	 ,	O
including  	including  	 VBG	O
also  	also  	 RB	O
premenopausal  	premenopausal  	 JJ	O
and  	and  	 CC	O
perimenopausal  	perimenopausal  	 JJ	B-NP
women  	women  	 NNS	I-NP
are  	are  	 VBP	O
warranted 	warranted 	 VBN	O
.  	.  	 .	O
